BLTE Share Price Performance
US$152.07
85.37 (127.99%)
28.1% undervalued intrinsic discount
US$211.50
Fair Value
Price US$152.07
AnalystConsensusTarget US$211.50
Fair ValueUS$211.50
Share Pricen/a
Belite Bio, Inc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
BLTE Community Narratives
AN
Fair Value US$211.5 28.1% undervalued intrinsic discount
Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$211.5
28.1% undervalued intrinsic discount
Fair Value
Profit Margin
56.52%
Future PE
39.21x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
Fair Value: US$211.5 28.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Belite Bio, Inc Key Details
About BLTE
- Founded
- 2016
- Employees
- 25
- CEO
- WebsiteView website
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
